Aptahem’s CEO on upcoming milestones
Aptahem has taken several steps forward in 2022. Recently, the biotech company passed a milestone with the start of the clinical phase I study with the sepsis candidate Apta-1. CEO Mikael Lindstam visited BioStock’s studio at Medicon Village in Lund to present the company and answer questions about the rights issue that is currently underway.
Watch the interview with Aptahem’s CEO Mikael Lindstam below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.